Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment

•Omadacycline is effective in patients with mild-to-moderate renal impairment.•Omadacycline has similar safety as linezolid for patients with acute bacterial skin and skin structure infections, and similar safety as moxifloxacin for patients with community-acquired bacterial pneumonia.•Omadacycline provides a once-daily regimen independent of dose adjustments.•Omadacycline is an option for those with or at risk of renal impairment or toxicity. Many antibiotics require dosage adjustments in patients with renal impairment. In Phase III studies, omadacycline was non-inferior to moxifloxacin and linezolid in adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), respectively. This analysis evaluated efficacy and safety measures from three omadacycline studies by patient renal function. Patients were stratified as having normal renal function (creatinine clearance >89 mL/min), mild renal impairment (creatinine clearance 60–89 mL/min) or moderate renal impairment (creatinine clearance